Results 191 to 200 of about 6,006,467 (356)

Activation of the alternative pathway of complement by mycobacteria and cord factor [PDF]

, 1980
V. D. Ramanathan, Jeffrey L. Curtis, J.L. Turk   +2 more
openalex   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Chronic kidney disease enhances alternative pathway activity: a new paradigm. [PDF]

J Clin Invest
Jalal DI, Thurman JM, Smith RJ.
europepmc   +1 more source

AAPM Task Group 298: Recommendations on certificate program/alternative pathway candidate education and training. [PDF]

J Appl Clin Med Phys, 2022
Prisciandaro JI, Burmeister JW, DeLuca PM, Gerbi BJ, Giger ML, Robar JL, Seibert JA.   +6 more
europepmc   +1 more source

Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium‐induced colitis

Clinical and Experimental Immunology, 2015
Michelle Elvington, Jennifer Schepp-Berglind, S. Tomlinson   +2 more
semanticscholar   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Pediatric Immunodeficiency Caused by Complement Classical and Alternative Pathway Defects Due to a Homozygous CFI Variant: A Case Report. [PDF]

Cureus
Wei J, Liu C, Tian M, Cao G, Li J.
europepmc   +1 more source

Correction to: Mathematical Modelling of Alternative Pathway of Complement System. [PDF]

Bull Math Biol, 2021
Bakshi S, Cunningham F, Nichols EM, Biedzka-Sarek M, Neisen J, Petit-Frere S, Bessant C, Bansal L, Peletier LA, Zamuner S, van der Graaf PH.   +10 more
europepmc   +1 more source

Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica [PDF]

, 1989
Elmar Wächter, Volker Brade
openalex   +1 more source

Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas

Molecular Oncology, EarlyView.
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo, Takuya Shirakihara, Akira Orimo   +11 more
wiley   +1 more source